STADA Arzneimittel AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Arzneimittel AG
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Stada CEO Peter Goldschmidt tells HBW Insight about his ambition to enter the US consumer health market as part of a push to take the business global.
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Bain Capital
- BIOCEUTICALS Arzneimittel AG
- Britannia Pharmaceuticals Limited
- Forum Bioscience Holdings, Ltd.
- Laboratorio Vannier S.A.
- Nidda Healthcare
- STADAPHARM GmbH
- LobSor Pharmaceuticals AB